Plain-English translation of NCT06552234 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called for people with advanced lung cancer that has a specific genetic change called ROS1 rearrangement. The study focuses on older adults (age 70 and up) or people who are frail, because these patients are often left out of typical cancer research. You would take this medication twice a day until your cancer stops responding to it or you experience side effects that are too difficult to manage.
Many cancer treatments are tested only in younger, healthier patients, leaving older and frail patients without clear answers about what will work for them. This trial exists to see if this medication is safe and effective specifically for people with advanced lung cancer who have frailty or advanced age.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth twice every day at home. You would visit the clinic regularly for blood tests, scans, and check-ins to see how you are responding and to monitor for any side effects. The treatment continues until your cancer progresses, you experience unacceptable side effects, or you and your doctor decide to stop. The study involves 30 participants and is recruiting across multiple hospitals in France.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
France